Performance data

Cell recovery and viability

Viability and recovery of T cell washing and concentration

Gentle processing enables >90% cell recovery while maintaining cell viability through T cell washing and concentration. High reproducibility was demonstrated over 10 runs.

200x T cell concentration

The CTS Rotea system was used to concentrate 500 million T cells in a starting volume of 1,000 mL down to 5 mL achieving 97% cell recovery while maintaining viability of 94%.

High PBMC recovery from a Leukopak bag

The CTS Rotea system can achieve approximately 90% PBMC recovery from a Leukopak bag in combination with a red blood cell lysis buffer across multiple donors (n=7).

Cell concentration and output volumes

High concentration in low volumes (200X)

5 x 10⁸  T cells concentrated into small volume.

Sample Data

Processing times

PBMC isolation with the CTS Rotea system vs Ficoll ® media

Flow cytometry data shows that PBMC cell isolation with the CTS Rotea instrument taking less than 30 minutes produces similar results to a 2-hour Ficoll® media separation.

PBMC composition from CTS Rotea system vs manual Ficoll® polymer. A single-donor Leukopak was split in two and PBMCs were separated using the CTS Rotea System or a manual Ficoll media protocol. The PBMCs were assessed using successive gating to identify monocytes, B, NK, and T cells. Processing with the CTS Rotea System (A) took less than 30 minutes and produced equivalent results as the 2-hour Ficoll separation (B).

T cell quality and composition

Flow cytometry data shows that CD4/CD8 T cell composition within the CD3⁺ total T cell population remains largely unchanged after washing and concentration with the CTS Rotea instrument.

T cell quality and composition after washing and concentration.


After PBMCs were isolated from healthy donors using the CTS Rotea System, the T cells were expanded in culture and assessed for CD4 and CD8 markers using flow cytometry. They were then washed and concentrated using the CTS Rotea System and assessed again. Comparison showed that CD4 and CD8 populations were consistent between the two analyses, demonstrating that the relative proportions were unaffected by CTS Rotea system processing.

For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products.